Contribution of infliximab population pharmacokinetic model for dose optimization in ulcerative colitis patients.

We read with great interest the paper by Pérez-Pitarch et al. entitled A pharmacokinetic approach to model-guided design of infliximab schedules in ulcerative colitis patients. We considered appropriate to highlight some aspects of the topic which were not addressed by the authors and according to our experience with therapeutic drug monitoring (TDM) of IFX in patients with inflammatory bowel disease (IBD). Although the causes of lack of response to anti-TNF drugs are multifactorial, the inter- and intra-individual pharmacokinetic (PK) variability plays an essential role. In that sense, two validated PPK models have been published for IFX in IBD patients. In our experience no correlation was found between individual model-predicted IFX concentrations (Cipred) and observed IFX concentrations (Cobs) when using the PPK model developed in UC in patients diagnosed of UC, whereas a good correlation was observed when using the Crohn disease (CD) PPK model with the same samples.

Citation

Eugènia Santacana Juncosa, Ariadna Padullés Zamora, Helena Colom Codina, Lorena Rodríguez Alonso, Jordi Guardiola Capo, Jordi Bas Minguet, Núria Padullés Zamora. Contribution of infliximab population pharmacokinetic model for dose optimization in ulcerative colitis patients. Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva. 2015 Nov 23

PMID: 26593058

search → result